SiBone $SIBN Shares Sold by Paradigm Capital Management Inc. NY

Key Points

• Paradigm Capital Management Inc. NY decreased its stake in SiBone by 8.0%, reducing its holdings to 1,275,455 shares worth approximately $17.9 million.
• Other institutional investors have mixed activity, with Johnson Investment Counsel Inc. acquiring a new position and GAMMA Investing LLC drastically increasing its stake by over 20,000% during the same quarter.
• SiBone's stock performance shows a market capitalization of $719.14 million and a recent earnings report that beat estimates with revenue of $48.63 million, exceeding analysts' expectations.

Paradigm Capital Management Inc. NY lessened its stake in shares of SiBone (NASDAQ:SIBN - Free Report) by 8.0% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,275,455 shares of the company's stock after selling 110,576 shares during the quarter. SiBone makes up approximately 1.0% of Paradigm Capital Management Inc. NY's holdings, making the stock its 28th largest holding. Paradigm Capital Management Inc. NY owned 2.99% of SiBone worth $17,895,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. ANTIPODES PARTNERS Ltd purchased a new position in shares of SiBone during the 1st quarter worth $34,000. Virtus Fund Advisers LLC purchased a new position in shares of SiBone during the 4th quarter worth $40,000. GAMMA Investing LLC lifted its stake in shares of SiBone by 20,352.6% during the 1st quarter. GAMMA Investing LLC now owns 3,886 shares of the company's stock worth $55,000 after purchasing an additional 3,867 shares during the period. Virtus Advisers LLC purchased a new position in shares of SiBone during the 1st quarter worth $58,000. Finally, Johnson Investment Counsel Inc. purchased a new position in shares of SiBone during the 1st quarter worth $148,000. Hedge funds and other institutional investors own 98.11% of the company's stock.

SiBone Stock Up 0.1%

NASDAQ:SIBN traded up $0.01 during mid-day trading on Friday, hitting $16.36. The company had a trading volume of 97,307 shares, compared to its average volume of 421,725. The firm has a market capitalization of $705.77 million, a price-to-earnings ratio of -29.39 and a beta of 0.81. SiBone has a 1 year low of $11.70 and a 1 year high of $20.05. The business has a fifty day simple moving average of $16.92 and a 200-day simple moving average of $16.51. The company has a current ratio of 8.38, a quick ratio of 7.00 and a debt-to-equity ratio of 0.21.

SiBone (NASDAQ:SIBN - Get Free Report) last posted its quarterly earnings results on Monday, August 4th. The company reported ($0.14) EPS for the quarter, topping analysts' consensus estimates of ($0.19) by $0.05. SiBone had a negative return on equity of 14.20% and a negative net margin of 12.83%.The business had revenue of $48.63 million during the quarter, compared to the consensus estimate of $48.12 million. SiBone has set its FY 2025 guidance at EPS. Equities analysts forecast that SiBone will post -0.78 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

SIBN has been the topic of a number of recent analyst reports. Wall Street Zen lowered SiBone from a "buy" rating to a "hold" rating in a research note on Saturday, August 9th. Cantor Fitzgerald set a $25.00 target price on SiBone and gave the stock an "overweight" rating in a research report on Monday, August 11th. Three investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, SiBone presently has a consensus rating of "Buy" and an average target price of $23.67.

Insider Activity

In related news, CFO Anshul Maheshwari sold 5,005 shares of the company's stock in a transaction on Wednesday, July 2nd. The stock was sold at an average price of $18.34, for a total transaction of $91,791.70. Following the completion of the transaction, the chief financial officer directly owned 217,078 shares in the company, valued at $3,981,210.52. This represents a 2.25% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Michael A. Pisetsky sold 3,329 shares of the company's stock in a transaction on Monday, August 18th. The stock was sold at an average price of $15.64, for a total value of $52,065.56. Following the transaction, the senior vice president owned 258,352 shares of the company's stock, valued at approximately $4,040,625.28. The trade was a 1.27% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 46,590 shares of company stock worth $765,137 over the last 90 days. Insiders own 4.00% of the company's stock.

About SiBone

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.